8 completed, 7 recruiting, 4 not yet recruiting, 4 unknown. 17 Phase 2, 10 Phase 1, 4 Not applicable, 4 Phase 3.
Follow Lymphoblastic Leukemia: new trials by email Literature Review of Lymphoblastic Leukemia trials Research Report on Lymphoblastic Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase II Study of the Combination of Subcutaneous Blinatumomab and Olverembatinib in Patients With Philadelphia Chromosome (ph)-Positive and/or BCR::ABL1 Positive Acute Lymphoblastic Leukemia (ALL) Blinatumomab, olverembatinib - Phase II Clinical Trial, Blinatumomab | Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | 60 | 2027-01-27 | 2026-10-07 |
| A Phase IB Trial of Subcutaneous Blinatumomab in Combination With Revumenib for Patients With KMT2A-rearranged Acute Lymphoblastic Leukemia Revumenib, Blinatumomab - Blinatumomab, Revumenib | Phase 1 | Not yet recruiting | M.D. Anderson Cancer Center | 20 | 2026-11-18 | 2026-08-12 |
| Intravenous Autologous CD19 CAR-T Cells for R/ R MM, B-ALL, and B-Cell Lymphoma Anti-BCMA and CD19 CART cells will be injected intravenously on a one-time basis - Lymphoblastic Leukemia, Relapsed or Refractory Multiple Myeloma (RRMM) | Not applicable | Recruiting | Anhui Provincial Hospital | 18 | 2025-04-16 | 2025-05-29 |
| Role of Cbc Indices in Acute Lymphoblastic Leukemia Patients complete blood count - Lymphoblastic Leukemia | Not applicable | Not yet recruiting | Sohag University | 100 | 2025-01-15 | 2024-12-24 |
| A Study to Investigate LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL) LP-118, Ponatinib, Vincristine - Acute Leukemia, Lymphoblastic Leukemia | Phase 1 / Phase 2 | Recruiting | University of Chicago | 15 | 2024-09-13 | 2026-03-18 |
| Treatment Protocol for Newky Diagnosed Adult Ph Positive ALL Vincristine, Dexamethasone, Imatinib - Lymphoblastic Leukemia, Philadelphia-Positive ALL | Not yet recruiting | PETHEMA Foundation | 150 | 2023-12-25 | 2023-12-19 | |
| TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II Dexamethasone, Mitoxantrone, PEG asparaginase - Lymphoblastic Leukemia | Phase 1 / Phase 2 | Recruiting | Tanja Andrea Gruber | 90 | 2023-11-03 | 2026-06-03 |
| Study of Brexucabtagene Autoleucel Plus Dasatinib in Adults With Acute Lymphoblastic Leukemia Dasatinib - Lymphoblastic Leukemia | Phase 1 | Active not recruiting | Stanford University | 8 | 2023-10-02 | 2026-10-06 |
| A Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL) BEAM-201 - Lymphoblastic Lymphoma, T-Cell Lymphoblastic Leukemia/Lymphoma | Phase 1 / Phase 2 | Active not recruiting | Beam Therapeutics Inc. | 5 | 2023-05-25 | 2025-01-13 |
| Exercise Training and NR Supplementation Trial to Improve Fitness in AYA HCT Survivors Nicotinamide Riboside, Placebo, Exercise Intervention - Lymphoblastic Leukemia, Cancer Survivors | Phase 2 | Recruiting | Children's Hospital of Philadelphia | 80 | 2023-02-23 | 2025-12-04 |
| Efficacy of Osteopathic Treatment on the Side Effects of Curative Treatments of Lymphoblastic Leukemia in Pediatrics osteopathy - Lymphoblastic Leukemia | Unknown | Assistance Publique - Hôpitaux de Paris | 15 | 2023-01-01 | 2022-12-23 | |
| Dual Anti-CD22/CD19 Chimeric Antigen Receptor-directed T Cells (CART2219.1) for Relapsed Refractory B-Lineage Leukaemia Phase I, Phase II - Lymphoblastic Leukemia, Lymphoblastic Leukemia, Acute, Childhood | Phase 1 / Phase 2 | Unknown | KK Women's and Children's Hospital | 48 | 2022-07-18 | 2023-03-09 |
| CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory B-Lineage Leukaemia / Lymphoma - A Feasibility Protocol Anti-CD19 CAR T-cells - Lymphoblastic Leukemia, Lymphoblastic Leukemia in Children | Phase 2 | Recruiting | KK Women's and Children's Hospital | 40 | 2022-03-15 | 2023-03-09 |
| CARTALL: Chimeric-Antigen Receptor (CAR) T-Cell Therapy for Relapsed/ Refractory T-Lineage Acute Lymphoblastic Leukaemia CAR T-cell therapy - Lymphoblastic Leukemia, Acute, Childhood, Lymphoblastic Leukemia | Phase 1 | Recruiting | National University Hospital, Singapore | 20 | 2021-09-08 | 2021-09-14 |
| ALaCART-B: Acute Leukemia and Chimeric Antigen Receptor-T Cell Therapy for B-lymphoblastic Leukemia. CAR T-cell therapy - Lymphoblastic Leukemia, Acute, Childhood, Lymphoblastic Leukemia | Phase 1 | Unknown | National University Hospital, Singapore | 40 | 2021-04-28 | 2021-09-09 |
| Study of Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphoblastic Leukemia With Inotuzumab Ozogamicin (InO) Inotuzumab ozogamicin, Dasatinib, Dexamethasone - Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia | Phase 2 | Recruiting | University of Chicago | 25 | 2021-03-02 | 2026-06-05 |
| An Open-Label Study of JZP-458 (RC-P) in Patients With Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic Lymphoma (LBL) IM JZP-458, IV JZP-458 - Acute Lymphoblastic Leukemia, Lymphoblastic Leukemia | Phase 2 / Phase 3 | Completed | Jazz Pharmaceuticals | 229 | 2019-12-27 | 2023-11-18 |
| Everolimus in Combination With Nelarabine, Cyclophosphamide and Etoposide in Lymphoblastic Leukemia/Lymphoma Everolimus, Nelarabine, Cyclophosphamide - Lymphoblastic Leukemia, Lymphoblastic Lymphoma | Phase 1 | Completed | Emory University | 8 | 2018-07-24 | 2023-07-21 |
| Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult T-LBL/ALL Dexamethasone, vincristine, Cyclophosphamide - Leukemia, Leukemia, Acute | Phase 2 / Phase 3 | Unknown | Nanfang Hospital, Southern Medical University | 80 | 2016-02-14 | 2018-06-21 |
| Nebulized Amphotericin B Lipid Complex in Invasive Pulmonary Aspergillosis in Paediatric Patients With Acute Leukaemia AMPHOTERICIN B - Invasive Pulmonary Aspergillosis, Lymphoblastic Leukaemia | Phase 2 | Completed | Fundació Sant Joan de Déu | 32 | 2011-10-01 | 2018-03-29 |
Showing 20 of 28. Sign in to see all of them.
Precursor Cell Lymphoblastic Leukemia-Lymphoma (28) · Leukemia (8) · Leukemia, Myeloid (3) · Lymphoma (3) · Multiple Myeloma (3) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (3) · Burkitt Lymphoma (2) · Graft vs Host Disease (2) · Hematologic Neoplasms (2) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (2) · Leukemia, Myeloid, Acute (2) · Lymphoma, Non-Hodgkin (2) · Myelodysplastic Syndromes (2) · Recurrence (2) · Anemia, Aplastic (1)
Hemic and Lymphatic Diseases (28) · Immune System Diseases (28) · Immunoproliferative Disorders (28) · Leukemia, Lymphoid (28) · Lymphatic Diseases (28) · Lymphoproliferative Disorders (28) · Neoplasms (28) · Neoplasms by Histologic Type (28) · Hematologic Diseases (27) · Leukemia (20) · Lymphoma (5) · Pathological Conditions, Signs and Symptoms (5) · Bone Marrow Diseases (4) · Disease Attributes (4) · Pathologic Processes (4)
Methotrexate (6) · Dexamethasone (5) · Mercaptopurine (5) · Vincristine (5) · Cyclophosphamide (4) · Cytarabine (4) · Etoposide (3) · blinatumomab (3) · pegaspargase (3) · ponatinib (3) · Calcium Dobesilate (2) · Dasatinib (2) · Doxorubicin (2) · Immunotherapy, Adoptive (2) · Sirolimus (2)
M.D. Anderson Cancer Center (3) · KK Women's and Children's Hospital (2) · National University Hospital, Singapore (2) · PETHEMA Foundation (2) · University of Chicago (2) · Abramson Cancer Center at Penn Medicine (1) · Anhui Provincial Hospital (1) · Assistance Publique - Hôpitaux de Paris (1) · Beam Therapeutics Inc. (1) · Children's Hospital of Philadelphia (1) · Emory University (1) · Fundació Sant Joan de Déu (1) · Gruppo Italiano Trapianto di Midollo Osseo (1) · Jazz Pharmaceuticals (1) · Kiadis Pharma (1)
United States (16) · Singapore (4) · Canada (3) · China (2) · Italy (2) · Spain (2) · Belgium (1) · Egypt (1) · France (1) · Germany (1) · Netherlands (1) · United Kingdom (1)
Allen Yeoh, M.D (2) · Dario Campana, M.D, PhD (2) · Elias J Jabbour, MD (2) · Alessandro Rambaldi, MD (1) · Alicia Kunin-Batson, Ph.D. (1) · Aloysius Ho, MD (1) · Andrea Velardi, MD (1) · Damiano Rondelli, MD (1) · Denis-Claude Roy, MD (1) · Himalee Sabnis, MD (1) · Jesus Estella, PhMD (1) · Josep M Ribera Santasusana, MD (1) · Karen K Ballen, MD (1)
PMID 41671463, PMID 20107229, PMID 25234438, PMID 35854224, PMID 36108304, PMID 39454281, PMID 42720434
2004 (1), R01CA254955 (1)